Elevance Health $ELV ( ▲ 1.25% ) is a massive health insurer disguised as a healthcare transformation story, with strong Blue Cross Blue Shield brand moats but facing margin pressure from rising medical costs. Hold with caution – solid market position but significant execution risk around their "whole health" strategy.

Before a restaurant sells any food, they need to buy it. That costs up to 35% on every dollar.

But Tipsy Putt’s business model cuts that number to less than 20%.

It’s called “Eatertainment,” the same model that turned TopGolf and Bowlero into billion-dollar companies.

Tipsy Putt is on a mission to dominate the mini golf slice of the Eatertainment space. Their mini golf, craft cocktails, and local eats have already drawn 5,000+ active members. And out of those three revenue streams, the highest-margin one (mini golf) requires no inventory whatsoever.

The result?

Five profitable California locations

22x revenue growth from 2020-24

75% more potential revenue per square foot

Now, they’re bringing this model to San Francisco, America's #3 foodie city. It’s going to address a Bay Area market of 7 million people. You can invest in Tipsy Putt’s SF flagship location before it opens.

I’m Ready to Invest

^{This is a paid advertisement for Tipsy Putt Regulation CF offering. Please read the offering circular at https://invest.tipsyputt.com/}

Think of Elevance Health as the middleman between you and your doctor – but a really, really big middleman. With 45.7 million medical members, they're one of the largest health insurers in America, though they've cleverly rebranded from the more familiar "Anthem" name to sound more... elevated? 🤷‍♂️

Here's how they make their money:

Health Benefits (86% of revenue) - This is the classic insurance game. Collect premiums from individuals, employers, and government programs, then pay out medical claims when people get sick. It's like running a massive casino where you're betting that your members will stay healthier than your actuaries predict. They serve everyone from individual consumers buying insurance on healthcare.gov to massive corporations covering thousands of employees.

CarelonRx (20% of revenue) - Their pharmacy services arm that handles prescription drugs for both their own members and external customers. Think of it as the behind-the-scenes logistics network that gets your medications from manufacturers to your medicine cabinet, while negotiating better prices along the way.

Carelon Services (10% of revenue) - The "whole health" vision in action. This includes everything from behavioral health services to data analytics that help other healthcare companies run more efficiently. It's their attempt to move beyond just paying claims to actually improving health outcomes.

The company operates under multiple brands depending on where you live. In 14 states, they're the exclusive Blue Cross and Blue Shield licensee (that's the brand recognition goldmine), while in other markets they operate as Wellpoint, Simply Healthcare, or just Carelon.

Key metrics they obsess over:

In the healthcare insurance thunderdome, Elevance is definitely one of the big players, but they're not the biggest kid on the block. That honor goes to UnitedHealth Group, followed by Anthem's frenemies like Cigna, Aetna (now owned by CVS), and Humana.

Their secret weapon? Those Blue Cross and Blue Shield licenses. In 14 states plus DC, they have exclusive or near-exclusive rights to use the most trusted brand name in health insurance. It's like having the McDonald's franchise rights in major metropolitan areas – people know and trust the brand, even if they don't know who actually owns it.

But here's where it gets interesting (and litigious): Elevance just settled a massive antitrust lawsuit that accused the Blue Cross Blue Shield system of essentially carving up the country like a healthcare mafia. The settlement, which cost them $666 million for the provider portion alone, has loosened some of those exclusive arrangements. Now some large employers can request bids from multiple Blue plans, which could intensify competition.

Recent competitive challenges:

But they're fighting back:

Let's talk dollars and cents, because that's what really matters when you're thinking about buying stock in a company.

Revenue Breakdown (2024):

The good news: Total revenue grew 3.3% to $177B, driven by premium rate increases and growth in their pharmacy business.

The concerning news: Operating margins are under pressure. Their benefit expense ratio (how much of premium dollars go to medical costs) jumped from 87.0% to 88.5% ↗️. In plain English, medical costs are rising faster than they can raise premiums, especially in Medicaid where government reimbursement rates are... let's call them "challenging."

Customer Mix Matters:

Cash Flow Reality Check: Operating cash flow dropped significantly to $5.8B from $8.1B ↘️, primarily due to that Medicaid membership decline and working capital changes. They're still generating solid cash, but the trend isn't great.

Capital Allocation:

The Verdict: Fairly Valued (with significant uncertainty)

Key assumptions driving the valuation:

The Bottom Line: Elevance is a well-managed company in a tough industry that's trying to reinvent itself while dealing with significant near-term headwinds. The stock price reflects this uncertainty – it's not obviously cheap, but it's not obviously expensive either. Success depends on execution of a complex transformation strategy while navigating a challenging regulatory environment.

Medical Loss Ratio Trends - If this stays above 88% for multiple quarters, margin recovery becomes much harder

Medicare Star Ratings - 2026 ratings (released October 2025) will determine whether they can recover that $183M revenue hit

Medicaid Membership Stabilization - Watch for when the post-COVID eligibility redeterminations finally end and membership starts growing again

Carelon Services Growth - This is their bet on the future – if revenue growth slows below 20%, the transformation story gets harder to believe

Debt Management - With $42.7B in net debt, watch interest coverage ratios and any signs of financial stress during economic downturns

Remember: Healthcare is a long-term game where regulatory changes can make or break investment returns. This isn't a stock for day traders – it's for investors who understand that healthcare transformation takes years, not quarters.

AI-written, human-approved

Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.